Moreover, pharmacogenomic analyses suggest that fedratinib may exhibit utility in head and neck squamous cell carcinoma (HNSCC) exhibiting low KRT18 expression (Gu et al., 2022). The gene discussed is KRT18; the disease is head and neck squamous cell carcinoma.